1150308-94-3 Usage
Chemical compound
A substance formed by a chemical reaction, often used in research and medicinal applications.
Molecular structure
Consists of a pyrrolidin-3-amine core with a N,N-dimethyl group and a 5-amino-2-chlorobenzyl substituent.
Pyrrolidin-3-amine core
A central part of the molecule that provides its basic structure and properties.
5-amino-2-chlorobenzyl substituent
A functional group attached to the core, which influences the molecule's reactivity and potential pharmacological properties.
Potential pharmacological properties
The compound is being studied for its potential use in treating various medical conditions.
Structure and reactivity
The compound's unique structure and reactivity make it a valuable tool for understanding biological systems and developing new drugs.
Research interest
Its unique properties and potential applications make it a subject of interest for researchers in various fields.
Applications
The compound is used in research and medicinal applications, contributing to the development of new drugs and therapies.
Study and development
Ongoing research is being conducted to better understand the compound's properties, reactivity, and potential applications in treating medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1150308-94-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,0,3,0 and 8 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1150308-94:
(9*1)+(8*1)+(7*5)+(6*0)+(5*3)+(4*0)+(3*8)+(2*9)+(1*4)=113
113 % 10 = 3
So 1150308-94-3 is a valid CAS Registry Number.
1150308-94-3Relevant academic research and scientific papers
FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS
-
Page 234, (2008/06/13)
The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.
